drugset
drugset / Trial / NCT05940883

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects

NCT05940883 ↗

Phase 1 Completed 36 enrolled Simcere Pharmaceutical Co., Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics(PK) of Y-2 sublingual tablet in healthy adult subjects.

Timeline

Start
2023-09-06
Primary completion
2023-11-21
Completion
2023-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Y-2 Sublingual Tablet Unknown — Other

Indications

No indication recorded.